In a research report published Friday, Griffin analyst Keith Markey reiterated a Buy rating on shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) with a price …
In a research report issued yesterday, Griffin analyst Keith Markey reiterated a Buy rating on shares of Synthetic Biologics Inc (NYSEMKT:SYN) and raised the price …
